Shopping Cart 0
Cart Subtotal
AED 0

Biotest AG (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary, Spain and in Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.

Biotest AG (BIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10

Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biotest AG, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12

Biotest Enters Into Research Agreement With EpiVax 13

Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15

Licensing Agreements 16

Affibody Enters into Licensing Agreement with Biotest 16

Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17

Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18

CEVEC Pharma Enters into Licensing Agreement with Biotest 19

Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20

Equity Offering 21

ADMA Biologics Raises USD40 Million in Public Offering of Shares 21

Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23

Asset Transactions 24

ADMA Biologics Acquires Certain Assets from Biotest Pharma 24

Acquisition 26

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Biotest AG-Key Competitors 27

Biotest AG-Key Employees 28

Biotest AG-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 32

Strategy And Business Planning 32

Jun 20, 2018: Biotest opens third plasma collection centre in Czech Republic 32

Jan 24, 2018: Biotest opens second plasma collection center in the Czech Republic 33

May 16, 2017: Biotest opens seventh plasma collection center in Hungary 34

Financial Announcements 35

Aug 14, 2018: Biotest sales increase to EUR 200.7 million in the first half of 2018 35

Mar 22, 2018: Biotest reaches 2017 profit guidance 36

Nov 14, 2017: Biotest generates revenues of EUR 377.8 million in the first nine months of 2017 37

May 10, 2017: Biotest will realize EUR 110.5 million in the first quarter of 2017 38

Product News 39

05/03/2018: New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors 39

Other Significant Developments 40

Oct 11, 2017: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Biotest AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10

Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12

Biotest Enters Into Research Agreement With EpiVax 13

Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15

Affibody Enters into Licensing Agreement with Biotest 16

Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17

Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18

CEVEC Pharma Enters into Licensing Agreement with Biotest 19

Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20

ADMA Biologics Raises USD40 Million in Public Offering of Shares 21

Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23

ADMA Biologics Acquires Certain Assets from Biotest Pharma 24

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Biotest AG, Key Competitors 27

Biotest AG, Key Employees 28

Biotest AG, Other Locations 29

Biotest AG, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Biotest AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Biotest AG (Biotest) provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary, Spain and in Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.

Biotest AG (BIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10

Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biotest AG, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12

Biotest Enters Into Research Agreement With EpiVax 13

Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15

Licensing Agreements 16

Affibody Enters into Licensing Agreement with Biotest 16

Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17

Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18

CEVEC Pharma Enters into Licensing Agreement with Biotest 19

Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20

Equity Offering 21

ADMA Biologics Raises USD40 Million in Public Offering of Shares 21

Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23

Asset Transactions 24

ADMA Biologics Acquires Certain Assets from Biotest Pharma 24

Acquisition 26

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Biotest AG-Key Competitors 27

Biotest AG-Key Employees 28

Biotest AG-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 32

Strategy And Business Planning 32

Jun 20, 2018: Biotest opens third plasma collection centre in Czech Republic 32

Jan 24, 2018: Biotest opens second plasma collection center in the Czech Republic 33

May 16, 2017: Biotest opens seventh plasma collection center in Hungary 34

Financial Announcements 35

Aug 14, 2018: Biotest sales increase to EUR 200.7 million in the first half of 2018 35

Mar 22, 2018: Biotest reaches 2017 profit guidance 36

Nov 14, 2017: Biotest generates revenues of EUR 377.8 million in the first nine months of 2017 37

May 10, 2017: Biotest will realize EUR 110.5 million in the first quarter of 2017 38

Product News 39

05/03/2018: New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors 39

Other Significant Developments 40

Oct 11, 2017: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Biotest AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Biotest AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Biotest AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Biotest AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Biotest AG, Deals By Therapy Area, 2012 to YTD 2018 9

Biotest AG, Medical Devices Deals, 2012 to YTD 2018 10

Biotest AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 12

Biotest Enters Into Research Agreement With EpiVax 13

Biotest Enters Into Co-Marketing Agreement With Merz Pharma And Vianex 14

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 15

Affibody Enters into Licensing Agreement with Biotest 16

Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 17

Adma Biologics Amends Licensing Agreement With Biotest For IGIV 18

CEVEC Pharma Enters into Licensing Agreement with Biotest 19

Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20

ADMA Biologics Raises USD40 Million in Public Offering of Shares 21

Biotest Completes Rights Offering Of Preference Shares For USD 99.5 Million 23

ADMA Biologics Acquires Certain Assets from Biotest Pharma 24

Grifols Shared Services North America Acquires Biotest for USD286 Million 26

Biotest AG, Key Competitors 27

Biotest AG, Key Employees 28

Biotest AG, Other Locations 29

Biotest AG, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Biotest AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.